Screener
Aclaris Therapeutics ACRS Operating Income
Operating Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Licensing | 1,235 | 1,335 | 2,628 | 2,345 |
| Revaluation of contingent consideration | 300 | 1,500 | 300 | 1,800 |
| Total costs and expenses | 25,867 | 20,185 | 50,055 | 39,724 |
| Loss from operations | (24,238) | (18,408) | (46,430) | (36,492) |
| Other income: | ||||
| Interest income | 1,761 | 2,018 | 3,275 | 4,184 |
| Non-cash royalty income | 972 | 961 | 1,826 | 1,794 |
| Total other income | 2,733 | 2,979 | 5,101 | 5,978 |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's operating income?
- Aclaris Therapeutics (ACRS) reported operating income of -$24.24M in Q2 2026.
- How has Aclaris Therapeutics's operating income changed year-over-year?
- Aclaris Therapeutics's operating income decreased by 31.7% year-over-year, from -$18.41M to -$24.24M.
- What is the long-term trend for Aclaris Therapeutics's operating income?
- Over 4 years (2021 to 2025), Aclaris Therapeutics's operating income has grown at a -3.9% compound annual growth rate (CAGR), from -$89.72M to -$76.38M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Aclaris Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude